Successful use of recombinant factor IX concentrate (Nonacog-alfa, benefix®) in two patients with severe hemophilia B and total knee replacement (TKR)

被引：0
|
作者：
Gerhardt, Andrea [1 ]
Stahlschmidt, Kristina [2 ]
Ilg, Ansgar [1 ]
Scharf, Rudiger E. [1 ]
Zotz, Rainer B. [1 ]
机构：
[1] Univ Dusseldorf, Med Ctr, Dept Hemostasis & Transfus Med, D-4000 Dusseldorf, Germany
[2] Univ Dusseldorf, Med Ctr, Dept Orthopaed Surg, D-4000 Dusseldorf, Germany
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3947
引用
收藏
页码：54B / 54B
页数：1
相关论文
共 50 条
  • [1] Successful use of recombinant factor IX (rFIX, nonacog-alfa, Benefix) in two patients with severe hemophilia B and total knee replacement (TKR)
    Gerhardt, A.
    Stahlschmidt, K.
    Zotz, R.
    Krauspe, R.
    Scharf, R.
    Ilg, A.
    [J]. HAEMOPHILIA, 2008, 14 : 11 - 11
  • [2] SAFETY OF BeneFIX® (NONACOG ALFA, RECOMBINANT HUMAN FACTOR IX) FOR USUAL USE IN PEDIATRIC PATIENTS: RESULTS FROM A PROSPECTIVE REGISTRY OF EUROPEAN HEMOPHILIA B PATIENTS
    Rendo, Pablo
    Berntorp, Erik
    [J]. PEDIATRIC BLOOD & CANCER, 2010, 54 (06) : 811 - 811
  • [3] Use of recombinant factor IX (benefix) in HIP replacement in a patient with severe haemophilia B
    Severin, K.
    Heyl, M.
    Compes, M.
    Steinmetz, H. T.
    Schmitz, S.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 114 - 114
  • [4] Body mass index-dependent pharmacokinetic analysis of an investigational recombinant factor IX product, IB1001 (trenonacog alfa) and a commercial factor IX product, Nonacog Alfa (BeneFIX) in Hemophilia B patients
    Drobic, Bojan
    Hua, Yi
    Babinchak, Tim
    Hall, Christine
    [J]. HAEMOPHILIA, 2014, 20 : 13 - 13
  • [5] Head-to-head comparative study of the pharmacokinetic behavior of a high-purity factor ix concentrate (alphanine®) and a recombinant factor ix (benefix®) in patients with severe hemophilia B
    Aznar, J. A.
    Moret, A.
    Cabrera, N.
    Matysiak, M.
    Zavilska, K.
    Gercheva, L.
    Antonov, A.
    Woodward, M. K.
    Paez, A.
    Lissitchkov, T.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 99 - 99
  • [6] Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients
    Rendo, Pablo
    Berntorp, Erik
    Keeling, David M.
    Makris, Michael
    Hermans, Cedric R.
    Mauser-Bunschosten, Ereline Pauline
    Musso, Roberto
    Tagliaferri, Annarita
    Kollmer, Carl
    Baumann, James
    Charnigo, Robert
    [J]. BLOOD, 2010, 116 (21) : 1504 - 1504
  • [7] Evaluation of the safety and efficacy of recombinant factor IX (nonacog alfa) in minimally treated and previously treated Chinese patients with hemophilia B
    Renchi, Y.
    Zhao, Y.
    Wang, X.
    Sun, J.
    Jin, J.
    Wu, D.
    Charnigo, R.
    O'Brien, A.
    Rendo, P.
    Zhong, Z.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 356 - 356
  • [8] Aggressive treatment of ICH/ECH in a neonate with severe hemophilia B with recombinant Factor IX (BeneFix®) infusion
    Guilcher, GMT
    Hand, JP
    Harvey, M
    Scully, MF
    [J]. PEDIATRIC RESEARCH, 2003, 53 (04) : 296A - 296A
  • [9] Pharmacokinetic Profile of Nonacog Gamma (recombinant factor IX) in Previously-Treated Patients with Severe or Moderately Severe Hemophilia B
    Windyga, Jerzy
    Lissitchkov, Toshko Jelev
    Chapman, Miranda
    Tangada, Srilatha D.
    Chatterjee, Nirjhar
    [J]. BLOOD, 2016, 128 (22)
  • [10] Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B
    Fukutake, Katsuyuki
    Taki, Masashi
    Matsushita, Tadashi
    Sakai, Michio
    Takata, Ami
    Yamaguchi, Hiromi
    Karumori, Toshiyuki
    [J]. HAEMOPHILIA, 2019, 25 (04) : E247 - E256
12345